Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells.
about
Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate CancerCellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressorEpigenetic modulators as therapeutic targets in prostate cancerAndrogens upregulate Cdc25C protein by inhibiting its proteasomal and lysosomal degradation pathwaysNovel Imidazopyridine Derivatives Possess Anti-Tumor Effect on Human Castration-Resistant Prostate Cancer CellsAntiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cellsCellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDAC) inhibitors in prostate cancer cell growth suppression.Human prostatic acid phosphatase: structure, function and regulation.Enhanced suppression of proliferation and migration in highly-metastatic lung cancer cells by combination of valproic acid and coumarin-3-carboxylic acid and its molecular mechanisms of action.Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.Androgen receptor signaling in prostate cancer.Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.Valproic Acid-Functionalized Cyclometalated Iridium(III) Complexes as Mitochondria-Targeting Anticancer Agents.The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
P2860
Q26742062-8CEA838D-E22A-45BE-B927-5E883DFCCED3Q26863333-96297361-5E91-4178-A68B-296B3AFB271EQ28071912-C5D3B5D1-666D-4C8A-9636-5A0BE84A2F8FQ28397032-610454CF-0551-4791-BEE7-01B602C98C21Q28545928-7E87DE1F-BFC8-4636-8503-B4CAF75249E8Q34115708-60CE090D-D17D-48F1-AD1B-413EAEEFDD3BQ35857477-77C4EB80-0E58-4F9F-AAC4-37721BDB64FAQ36913762-4135BBED-33B5-4D2F-B0AE-7838E6783D4AQ37039303-6AB493DF-8AC9-47F9-8C09-DA65554F53D8Q37190106-8F4E3C0A-D800-4116-8B36-8DD9726D530AQ37445211-B141EAA0-D418-46EE-A33C-1EC225680659Q38175320-9457CEC5-F756-461D-94D1-6AE011F8D9B4Q47291146-7B520AA4-5717-49A3-9F1E-DC82227AE4AFQ47763729-73AB7C6F-CD85-4F80-8CF2-7A6CC09DB7BDQ53156735-38DA0A5C-6B11-42BC-BECB-1289DB7C00B9
P2860
Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Histone deacetylase inhibitor ...... ness of prostate cancer cells.
@ast
Histone deacetylase inhibitor ...... ness of prostate cancer cells.
@en
type
label
Histone deacetylase inhibitor ...... ness of prostate cancer cells.
@ast
Histone deacetylase inhibitor ...... ness of prostate cancer cells.
@en
prefLabel
Histone deacetylase inhibitor ...... ness of prostate cancer cells.
@ast
Histone deacetylase inhibitor ...... ness of prostate cancer cells.
@en
P2093
P2860
P1433
P1476
Histone deacetylase inhibitor ...... eness of prostate cancer cells
@en
P2093
Fen-Fen Lin
Ming-Fong Lin
Nagendra K Chaturvedi
Shougiang Ouyang
Yu-Wei Chou
P2860
P304
P356
10.1016/J.CANLET.2011.07.015
P407
P577
2011-07-22T00:00:00Z